Education
About Us
Working with TipRanks
Follow Us
Disc Medicine (IRON)
NASDAQ:IRON
IRON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.64 - $68.73
Previous CloseN/A
Volume41.94K
Average Volume (3M)504.98K
Market Cap
$1.34B
Enterprise Value$1.43B
Total Cash (Recent Filing)$1.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.78
Next Earnings
May 19, 2025EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.99
Shares Outstanding34,569,042
10 Day Avg. Volume803,873
30 Day Avg. Volume504,982
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.34K
Enterprise Value/Ebitda-13.24
Forecast
1Y Price Target
$98.50Price Target Upside154.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Commercialization ProspectsCommercialization will be facilitated by an established diagnosis code and pre-existing dataset of payor claims.
Financial PerformanceIRON ended the year with $489.9MM in cash, cash equivalents and marketable securities.
Regulatory EngagementApproval is likely given positive regulatory engagement thus far.
Bears Say
Potential Conflicts Of InterestInvestors should be aware of potential conflicts of interest due to Wedbush Securities doing business with companies covered in its reports.
---
Ownership Overview
26.62% Insiders
13.42% Mutual Funds
33.60% Other Institutional Investors
18.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $25.64 and its highest was $68.73 in the past 12 months.
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $1.34B.
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is May 19, 2025 which is in 36 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Feb 27, 2025. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.096 by $0.146.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -1.11.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 34,569,042 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.096. Following the earnings report the stock price went up 0.073%.
Which hedge fund is a major shareholder of Disc Medicine?
Currently, no hedge funds are holding shares in IRON
---
Disc Medicine Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$98.50 (154.32% Upside)
$98.50 (154.32% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 713.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $41.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.88%
12-Months-Change
Fundamentals
Return on Equity
-27.73%
Trailing 12-Months
Asset Growth
34.99%
Trailing 12-Months
Company Description
Disc Medicine
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
---
IRON Stock 12 Month Forecast
Average Price Target
$98.50
▲(154.32% Upside)
Technical Analysis
BioCryst
―
Agios Pharma
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Best Analysts Covering IRON
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
+6.35%
reiterated a buy rating last month
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +6.35% per trade.
---